| 000 | 01721 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515071457.0 | ||
| 264 | 0 | _c20080215 | |
| 008 | 200802s 0 0 fre d | ||
| 022 | _a0755-4982 | ||
| 024 | 7 |
_a10.1016/j.lpm.2006.12.033 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEtienne, Manuel | |
| 245 | 0 | 0 |
_a[Management of fungal urinary tract infections]. _h[electronic resource] |
| 260 |
_bPresse medicale (Paris, France : 1983) _cDec 2007 |
||
| 300 |
_a1899-906 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAmphotericin B _xtherapeutic use |
| 650 | 0 | 4 |
_aAntifungal Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCandida albicans _xisolation & purification |
| 650 | 0 | 4 |
_aCandidiasis _xdiagnosis |
| 650 | 0 | 4 |
_aCross Infection _xepidemiology |
| 650 | 0 | 4 |
_aCystitis _xmicrobiology |
| 650 | 0 | 4 |
_aDeoxycholic Acid _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluconazole _xadministration & dosage |
| 650 | 0 | 4 |
_aFungemia _xdiagnosis |
| 650 | 0 | 4 |
_aFungi _xisolation & purification |
| 650 | 0 | 4 | _aHealth Status |
| 650 | 0 | 4 | _aHospital Mortality |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMycoses _xdiagnosis |
| 650 | 0 | 4 | _aPrimary Prevention |
| 650 | 0 | 4 |
_aPyelonephritis _xmicrobiology |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aUrinary Catheterization _xadverse effects |
| 650 | 0 | 4 |
_aUrinary Tract Infections _xdiagnosis |
| 650 | 0 | 4 |
_aUrine _xmicrobiology |
| 700 | 1 | _aCaron, François | |
| 773 | 0 |
_tPresse medicale (Paris, France : 1983) _gvol. 36 _gno. 12 Pt 3 _gp. 1899-906 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.lpm.2006.12.033 _zAvailable from publisher's website |
| 999 |
_c17084110 _d17084110 |
||